Evotec offers unique proteomics and metabolomics services to address key issues in drug and biomarker discovery. We continuously advance our capabilities in mass spectrometry-based proteomics and metabolomics to ensure unrivalled comprehensiveness and data quality when analysing cells, animal models and patient samples.
Our offering comprises:
- Global protein expression and modification analysis enabling unbiased drug mode of action and target engagement studies
- Proteome-wide discovery of biomarker candidates in cells, tissues and body fluids, complemented by targeted mass spectrometry platforms for validation of investigational protein biomarkers
- Evotec Cellular Target Profiling™ and drug photoaffinity labelling for target deconvolution of bioactive compounds
Global Proteome Expression and Modification Analysis
Evotec offers advanced technologies for unbiased protein expression and modification analysis of almost any type of biological samples including cells, tissues, body fluids, insects, fungi, and plants. Evotec’s global proteomics platforms support target discovery on the functional protein level.
Likewise, they enable unbiased mode of action studies, the identification of specific pharmacodynamic read-outs and lead compound prioritisation according to cellular activity profiles.
Biomarker discovery and validation
Evotec offers a unique platform of innovative proteomics and metabolomics technologies to address key issues in translational biomarker discovery and validation in various therapeutic areas. Both the expertise and the data processing infrastructure are in place for accurate quantification across many different samples, enabling integrated, large-scale projects to discover and validate diagnostic, pharmacodynamic or predictive biomarkers.
Our offering comprises:
- Tailor-made workflows enabling either proteome profiling for quantitative analysis across thousands of samples, or deep proteome profiling for detection of more than 10,000 proteins from cells or tissues
- In-depth, quantitative protein biomarker discovery in body fluid samples such as plasma and CSF
- Industrialised, QMS supported process enables analysis of thousands of samples with constant high quality
Clinical Proteomics
Evotec offers a flexible and versatile platform for the support of clinical studies from medium sized and large cohorts to support human patient studies as well as animal health activities. Using high-throughput proteomics workflows we analyze body fluids such as plasma, serum, cerebrospinal fluid, urine but also fresh-frozen or FFPE tissue or other suited clinical samples.
This unbiased approach allows to identify proteins that can serve as novel diagnostic or predictive biomarkers to allow patient stratification for individualised therapies but also broadens the understanding about molecular mechanisms involved in disease progression.
As part of a strategic alliance with Seer Inc., Evotec is the first Center of Excellence in Europe to offer access to the fully automated nanoparticle based ProteographTM platform. This enables us to perform plasma and serum proteomics at an unprecedented depth of up to 5,000 identified and quantified proteins.
Our offering comprises
- Support with study design and sample collection to generate optimal input material for proteomics or multi-omics studies. Our bioinformatics experts and specialists for different therapeutic areas will consult you with regard to study size, selection of treatment paradigm, collection of patient metadata and provide you with guidelines, e.g. for minimising technical variability between samples for multi-centric studies. Evotec’s quality control comprises standardized recording of sample properties (e.g. automated analysis of hemoglobin levels) upon receipt and takes into account possible sources of contamination that might confound data interpretation.
Chemical proteomics and target deconvolution
Evotec scientists have pioneered chemical proteomics applications to support target deconvolution of bioactive compounds emerging from phenotypic screens. Cellular target identification is the crucial step to enable further drug optimisation and development.
Evotec Cellular Target Profiling™ is a powerful technology to identify specific cellular compound targets in lysates from any cell type or tissue. Evotec’s chemical proteomics offering further comprises photoaffinity labelling for covalent target capture in live cells.
Our offering comprises:
- Evotec’s chemical proteomics approaches use high-end quantitative mass spectrometry to reveal and verify specific cellular targets of a drug
- Evotec Cellular Target Profiling™ determines target-specific dissociation constants for the compound studied, ranking targets according to their likely physiological relevance
- Drug photoaffinity labelling supports binding site identification in protein targets and complexes
Chemical Proteomics - Drug Selectivity and Activity Profiling
Evotec has established a chemical proteomics platform which employs high-end quantitative mass spectrometry for compound selectivity analysis in the context of native proteomes and sub-proteomes. Selectivity data about cellular on- and off-target liabilities is particularly useful for informed decisions at various stages of drug development, for example in the lead optimisation phase or in the pre-clinical candidate selection process.
Our offering comprises:
- Evotec Cellular Target Profiling™ for unbiased, proteome-wide selectivity profiling to identify and quantify compound interactions with cellular on- and off-targets
MHC Peptidomics Profiling
Evotec has strong expertise in the analysis of MHC class I peptidomes of cells, animal tissues, and patient derived samples. The workflow enables the discrimination of biological samples based on presented peptides, the generation of target hypotheses, and the discovery of neo-antigens presented by tumours and infected cells.
Our offering comprises:
- High-end peptidomics workflow enabling the enrichment and the detection of MHC class I presented peptides
Metabolomics
Evotec has established expertise and state-of-the-art methodologies in targeted metabolomics for the functional analysis of metabolic networks with applications in health, biotechnology and microbiology.
Evotec offers unique in vitro, ex vivo and in vivo targeted metabolomics services to address key issues in biomarker discovery and/or validation in various therapeutic areas including cancer, metabolic syndrome, diabetes, CNS and cardiovascular diseases.
Applications of metabolomics include:
- Pre-clinical biomarker identification
- Disease mechanism and validation of animal models for disease
- Discovery of biomarkers for patient stratification as well as clinical safety and efficacy assessment
Our targeted metabolomics approach focuses on the analysis of specific group of metabolites related to certain metabolic pathways or a class of compounds including lipids (phospholipids, lysophospholipids, sphingolipids, and neutral lipids), endocannabinoids, eicosanoids, corticosteroids, neurosteroids, oxysterols, nucleotides free fatty acids, and nicotinamide metabolome.
Due to its sensitivity and specificity, our approach allows absolute quantitation of metabolites using selected reaction monitoring (SRM), with detection limit of ng/mL, in sample matrices (e.g. biofluids, cells, organs) and also in vivo on awake or anesthetised animals using microdialysis coupled with XLC-MS/MS.
Statistics and bioinformatics analysis
Evotec’s bioinformatics group developed strong expertise in the analysis of proteomics, transcriptomics, and other OMICs data supporting mode of action studies, the discovery of biomarker candidates, and the identification of novel targets.
Our offering comprises:
- Extensive quality control of experimental data using clustering and principal component analysis, outlier detection methods, and advanced normalisation methods